Global Geriatric Medicines Market Size, Share, Trends, Industry Analysis Report: By Therapeutics (Analgesics; Statins, Antidiabetic; Proton Pump Inhibitors, Anticoagulant, Antipsychotic, and Others), Condition, Distribution Channel, and Region (North Amer

The global geriatric medicines market size is expected to reach USD 340.50 billion by 2034, according to a new study by Polaris Market Research. The report “Geriatric Medicines Market Size, Share, Trends, Industry Analysis Report: By Therapeutics (Analgesics, Statins, Antidiabetic, Proton Pump Inhibitors (PPIs), Anticoagulant, Antipsychotic, and Others), Condition, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Geriatric medicines, also known as geriatric pharmacotherapy, refer to a specialized branch of medicine focused on the development, use, and management of pharmaceutical treatments designed specifically for elderly individuals. This area addresses the unique physiological changes and health challenges associated with aging, including chronic conditions such as cardiovascular diseases, diabetes, arthritis, neurological disorders, and respiratory diseases.

The geriatric medicines market is driven by the growing global aging population and the rising prevalence of chronic and age-related diseases such as cardiovascular conditions, diabetes, arthritis, and neurodegenerative disorders. Key opportunities in the market include advancements in personalized medicine, the development of age-specific drug formulations, and the expansion of healthcare infrastructure in emerging markets.

Trends such as the integration of digital health technologies, including telemedicine and wearable devices, are enhancing access to care and improving treatment adherence among older adults. The market is also seeing increasing investments in preventive healthcare and biosimilars to provide cost-effective solutions. Overall, the geriatric medicines market is poised for steady growth as demand for innovative and accessible treatments continues to rise globally.

Geriatric Medicines Market Report Highlights

The antidiabetic segment dominates the market due to the high prevalence of diabetes among the elderly, with rising demand for innovative treatments such as GLP-1 receptor agonists driving growth.

Cardiovascular diseases account for the largest geriatric medicines market share, driven by the significant burden of heart-related conditions in older adults, while neurological disorders are the fastest-growing segment due to the increasing prevalence of Alzheimer’s and Parkinson’s diseases.

Hospital pharmacies lead the market as they are primary points of care for elderly patients with chronic diseases, whereas online pharmacies are registering the fastest growth due to the convenience of home delivery and the rising adoption of digital health platforms.

North America dominates the market, supported by advanced healthcare infrastructure and a growing elderly population, while Asia Pacific is the fastest-growing region, fueled by its expanding geriatric demographic and improving healthcare access.

Polaris Market Research has segmented the geriatric medicines market report based on therapeutics, condition, distribution channel, and region:

By Therapeutics Outlook (Revenue-USD Billion, 2020 – 2034)

Analgesics

Statins

Antidiabetic

Proton Pump Inhibitors (PPIs)

Anticoagulant

Antipsychotic

Others

By Condition Outlook (Revenue-USD Billion, 2020 – 2034)

Cardiovascular Diseases

Neurological Disorders

Cancer

Diabetes & Metabolic Disorders

Respiratory Diseases

Others

By Distribution Channel Outlook (Revenue-USD Billion, 2020 – 2034)

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Regional Outlook (Revenue-USD Billion, 2020 – 2034)

North America

  • US
  • Canada
Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America


1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Source
3.2.1. Primary Source
3.2.2. Secondary Source
4. Global Geriatric Medicines Market Insights
4.1. Geriatric Medicines Market – Market Snapshot
4.2. Geriatric Medicines Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Growing Demand for Age-Specific Medications
4.2.1.2. Advancements in Personalized Medicine for Elderly Patients
4.2.2. Restraints and Challenges
4.2.2.1. High Cost of Geriatric Healthcare
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Geriatric Medicines Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Geriatric Medicines Market, by Therapeutics
5.1. Key Findings
5.2. Introduction
5.2.1. Global Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
5.3. Analgesics
5.3.1. Global Geriatric Medicines Market, by Analgesics, by Region, 2020–2034 (USD Billion)
5.4. Statins
5.4.1. Global Geriatric Medicines Market, by Statins, by Region, 2020–2034 (USD Billion)
5.5. Antidiabetic
5.5.1. Global Geriatric Medicines Market, by Antidiabetic, by Region, 2020–2034 (USD Billion)
5.6. Proton Pump Inhibitors (PPIs)
5.6.1. Global Geriatric Medicines Market, by Proton Pump Inhibitors (PPIs), by Region, 2020–2034 (USD Billion)
5.7. Anticoagulant
5.7.1. Global Geriatric Medicines Market, by Anticoagulant, by Region, 2020–2034 (USD Billion)
5.8. Antipsychotic
5.8.1. Global Geriatric Medicines Market, by Antipsychotic, by Region, 2020–2034 (USD Billion)
5.9. Others
5.9.1. Global Geriatric Medicines Market, by Others, by Region, 2020–2034 (USD Billion)
6. Global Geriatric Medicines Market, by Condition
6.1. Key Findings
6.2. Introduction
6.2.1. Global Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
6.3. Cardiovascular Diseases
6.3.1. Global Geriatric Medicines Market, by Cardiovascular Diseases, by Region, 2020–2034 (USD Billion)
6.4. Neurological Disorders
6.4.1. Global Geriatric Medicines Market, by Neurological Disorders, by Region, 2020–2034 (USD Billion)
6.5. Cancer
6.5.1. Global Geriatric Medicines Market, by Cancer, by Region, 2020–2034 (USD Billion)
6.6. Diabetes & Metabolic Disorders
6.6.1. Global Geriatric Medicines Market, by Diabetes & Metabolic Disorders, by Region, 2020–2034 (USD Billion)
6.7. Respiratory Diseases
6.7.1. Global Geriatric Medicines Market, by Respiratory Diseases, by Region, 2020–2034 (USD Billion)
6.8. Others
6.8.1. Global Geriatric Medicines Market, by Others, by Region, 2020–2034 (USD Billion)
7. Global Geriatric Medicines Market, by Distribution Channel
7.1. Key Findings
7.2. Introduction
7.2.1. Global Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
7.3. Hospital Pharmacy
7.3.1. Global Geriatric Medicines Market, by Hospital Pharmacy, by Region, 2020–2034 (USD Billion)
7.4. Retail Pharmacy
7.4.1. Global Geriatric Medicines Market, by Retail Pharmacy, by Region, 2020–2034 (USD Billion)
7.5. Online Pharmacy
7.5.1. Global Geriatric Medicines Market, by Online Pharmacy, by Region, 2020–2034 (USD Billion)
8. Global Geriatric Medicines Market, by Geography
8.1. Key Findings
8.2. Introduction
8.2.1. Geriatric Medicines Market Assessment, b y Geography, 2020–2034 (USD Billion)
8.3. Geriatric Medicines Market – North America
8.3.1. North America: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.3.2. North America: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.3.3. North America: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.3.4. Geriatric Medicines Market – US
8.3.4.1. US : Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.3.4.2. US : Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.3.4.3. U S: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.3.5. Geriatric Medicines Market – Canada
8.3.5.1. Canada: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.3.5.2. Canada: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.3.5.3. Canada: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.4. Geriatric Medicines Market – Europe
8.4.1. Europe: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.4.2. Europe: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.4.3. Europe: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.4.4. Geriatric Medicines Market – UK
8.4.4.1. UK: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.4.4.2. UK: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.4.4.3. UK: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.4.5. Geriatric Medicines Market – France
8.4.5.1. France: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.4.5.2. France: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.4.5.3. France: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.4.6. Geriatric Medicines Market – Germany
8.4.6.1. Germany: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.4.6.2. Germany: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.4.6.3. Germany: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.4.7. Geriatric Medicines Market – Italy
8.4.7.1. Italy: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.4.7.2. Italy: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.4.7.3. Italy: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.4.8. Geriatric Medicines Market – Spain
8.4.8.1. Spain: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.4.8.2. Spain: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.4.8.3. Spain: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.4.9. Geriatric Medicines Market – Netherlands
8.4.9.1. Netherlands: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.4.9.2. Netherlands: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.4.9.3. Netherlands: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.4.10. Geriatric Medicines Market – Russia
8.4.10.1. Russia: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.4.10.2. Russia: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.4.10.3. Russia: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.4.11. Geriatric Medicines Market – Rest of Europe
8.4.11.1. Rest of Europe: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.4.11.2. Rest of Europe: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.4.11.3. Rest of Europe: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.5. Geriatric Medicines Market – Asia Pacific
8.5.1. Asia Pacific: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.5.2. Asia Pacific: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.5.3. Asia Pacific: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.5.4. Geriatric Medicines Market – China
8.5.4.1. China: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.5.4.2. China: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.5.4.3. China: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.5.5. Geriatric Medicines Market – India
8.5.5.1. India: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.5.5.2. India: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.5.5.3. India: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.5.6. Geriatric Medicines Market – Malaysia
8.5.6.1. Malaysia: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.5.6.2. Malaysia: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.5.6.3. Malaysia: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.5.7. Geriatric Medicines Market – Japan
8.5.7.1. Japan: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.5.7.2. Japan: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.5.7.3. Japan: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.5.8. Geriatric Medicines Market – Indonesia
8.5.8.1. Indonesia: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.5.8.2. Indonesia: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.5.8.3. Indonesia: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.5.9. Geriatric Medicines Market – South Korea
8.5.9.1. South Korea: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.5.9.2. South Korea: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.5.9.3. South Korea: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.5.10. Geriatric Medicines Market – Australia
8.5.10.1. Australia: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.5.10.2. Australia: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.5.10.3. Australia: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.5.11. Geriatric Medicines Market – Rest of Asia Pacific
8.5.11.1. Rest of Asia Pacific: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.5.11.2. Rest of Asia Pacific: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.5.11.3. Rest of Asia Pacific: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.6. Geriatric Medicines Market – Middle East & Africa
8.6.1. Middle East & Africa: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.6.2. Middle East & Africa: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.6.3. Middle East & Africa: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.6.4. Geriatric Medicines Market – Saudi Arabia
8.6.4.1. Saudi Arabia: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.6.4.2. Saudi Arabia: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.6.4.3. Saudi Arabia: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.6.5. Geriatric Medicines Market – UAE
8.6.5.1. UAE: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.6.5.2. UAE: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.6.5.3. UAE: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.6.6. Geriatric Medicines Market – Israel
8.6.6.1. Israel: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.6.6.2. Israel: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.6.6.3. Israel: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.6.7. Geriatric Medicines Market – South Africa
8.6.7.1. South Africa: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.6.7.2. South Africa: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.6.7.3. South Africa: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.6.8. Geriatric Medicines Market – Rest of Middle East & Africa
8.6.8.1. Rest of Middle East & Africa: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.6.8.2. Rest of Middle East & Africa: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.6.8.3. Rest of Middle East & Africa: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.7. Geriatric Medicines Market – Latin America
8.7.1. Latin America: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.7.2. Latin America: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.7.3. Latin America: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.7.4. Geriatric Medicines Market – Mexico
8.7.4.1. Mexico: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.7.4.2. Mexico: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.7.4.3. Mexico: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.7.5. Geriatric Medicines Market – Brazil
8.7.5.1. Brazil: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.7.5.2. Brazil: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.7.5.3. Brazil: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.7.6. Geriatric Medicines Market – Argentina
8.7.6.1. Argentina: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.7.6.2. Argentina: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.7.6.3. Argentina: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
8.7.7. Geriatric Medicines Market – Rest of Latin America
8.7.7.1. Rest of Latin America: Geriatric Medicines Market, by Therapeutics, 2020–2034 (USD Billion)
8.7.7.2. Rest of Latin America: Geriatric Medicines Market, by Condition, 2020–2034 (USD Billion)
8.7.7.3. Rest of Latin America: Geriatric Medicines Market, by Distribution Channel, 2020–2034 (USD Billion)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. Pfizer Inc.
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. Novartis International AG
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. Sanofi
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. GlaxoSmithKline
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. Merck & Co.
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. AbbVie
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. AstraZeneca
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. Johnson & Johnson
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. Eli Lilly and Company
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. Roche
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings